2-Methoxy-2-methylpropan-1-amine → 9-fluoro-10-(3-hydroxy-3-methyl-but-1-ynyl)-N3-(2-methoxy-2-methyl-propyl)-5,6-dihydroimidazo[1,2-d][1,4]benzoxazepine-2,3-dicarboxamide
반응식
[C:1]([C:4]1[N:5]=[C:6]2[C:12]3[CH:13]=[C:14]([C:18]#[C:19][C:20]([OH:23])([CH3:22])[CH3:21])[C:15]([F:17])=[CH:16][C:11]=3[O:10][CH2:9][CH2:8][N:7]2[C:24]=1[C:25](O)=[O:26])(=[O:3])[NH2:2].[CH3:28][O:29][C:30]([CH3:34])([CH3:33])[CH2:31][NH2:32]>>[F:17][C:15]1[C:14]([C:18]#[C:19][C:20]([OH:23])([CH3:21])[CH3:22])=[CH:13][C:12]2[C:6]3[N:7]([C:24]([C:25]([NH:32][CH2:31][C:30]([O:29][CH3:28])([CH3:34])[CH3:33])=[O:26])=[C:4]([C:1]([NH2:2])=[O:3])[N:5]=3)[CH2:8][CH2:9][O:10][C:11]=2[CH:16]=1참가 물질
3
반응물 2
생성물 1
실험 절차
2-Carbamoyl-9-fluoro-10-(3-hydroxy-3-methyl-but-1-ynyl)-5,6-dihydroimidazo[1,2-d][1,4]benzoxazepine-3-carboxylic acid (0.05 g) was reacted with (2-methoxy-2-methylpropyl)amine similar to as described in Example 2 to afford 14.8 mg of 9-fluoro-10-(3-hydroxy-3-methyl-but-1-ynyl)-N3-(2-methoxy-2-methyl-propyl)-5,6-dihydroimidazo[1,2-d][1,4]benzoxazepine-2,3-dicarboxamide following reverse phase hplc purification. MS (Q1) 459 (M)+. 1H NMR (400 MHz, DMSO) δ 11.24 (t, 1H), 8.60 (d, J=8.5 Hz, 1H), 8.35 (s, 1H), 7.87 (s, 1H), 7.02 (d, J=10.6 Hz, 1H), 5.48 (s, 1H), 5.10-4.90 (m, 2H), 4.63-4.45 (m, 2H), 3.34 (d, J=5.6 Hz, 2H), 3.14 (s, 3H), 1.49 (s, 7H), 1.15 (s, 6H).